Abstract
Fungi are increasingly recognized as major clinical pathogens in critically ill patients. Emerging groups of fungal pathogens such as Candida and Cryptococcus spp. are most frequently isolated from clinical setup, including filamentous fungi. Assessment of risk factors of these infections such as hospital-acquired fungal infection and environmental factors, including changes in medical practices and epidemiology as well as fungal infection mediated immunomodulation have provided important therapeutic options in the diagnosis of the fungal infections for clinicians. This review aims to furnish information on the factors affecting invasive fungal infections in a clinical scenario, especially for immunocompromised patients. A review of the recently published literature via PubMed, Elsevier and Medline database was performed. Relevant invasive fungal diseases and their worldwide cases were reviewed. Data on the immune response to the fungal infections in terms of release of anti-fungal effectors have been provided. Information on the anti-fungal mechanistic action via upregulation of immunity through predominant cytokines has been summarized, as well as factors affecting disease scenario of invasive fungal infections in clinical practices. The epidemiology and clinical features of fungal infections have also been reviewed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Enoch, D. and N. Brown (2006). Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 55: 809–818.
Gullo, A. (2009). Invasive fungal infections. Drugs 69: 65–73.
Pagano, L, M. Caira, A. Candoni, M. Offidani, L. Fianchi, and B. Martino (2006). The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Hematologica: J. Eur. Hematol. Assoc. 91: e1068.
Chayakulkeeree, M, M. Ghannoum, and J. Perfect (2006). Zygomycosis: The re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25: 215–229.
Garber, G. (2001). An overview of fungal infections. Drugs 61: 1–12.
Schuetz, A. (2013). Invasive fungal infections. Clin. Lab. Med. 33: 505–525.
Lehrnbecher, T., C. Frank, K. Engels, S. Kriener, A. H. Groll, and D. Schwabe (2010). Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 61: 259–265.
Upton, A. and K. Marr (2006). Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr. Infect. Dis. Rep. 8: 434–441.
Natesan, S. (2016). Emerging fungal infections in cancer patients — A brief overview. Med. Mycol. 2: e8521.
Leventakos, K., R. Lewis, and D. Kontoyiannis (2010). Fungal infections in leukemia patients: How do we prevent and treat them?. Clin. Infect. Dis. 50: 405–415.
Vincent, J., J. Rello, and J. Marshall (2009). International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: e2323.
Paramythiotou, E., F. Frantzeskaki, A. Flevari, A. Armaganidis, and G. Dimopoulos (2014). Invasive fungal infections in the ICU: How to approach, how to treat. Molecules 19: 1085–1119.
Wisplinghoff, H., T. Bischoff, S. Tallent, H. Seifert, R. Wenzel, and M. Edmond (2004). Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39: 309–317.
de Irala-Estévez, J., D. Martínez-Concha, C. Diaz-Molina, J. Masa-Calles, A. Serrano del Castillo, and R. Fernández-Crehuet Navajas (2001). Comparison of different methodological approaches to identify risk factors of nosocomial infection in intensive care units. Intensive Care Med. 27: 1254–1262.
Hobson, R. (2003). The global epidemiology of invasive Candida infections — is the tide turning?. J. Hosp. Infect. 55: 159–168.
Chapman, R. (2003). Candida infections in the neonate. Curr. Opin. Pediatr. 15: 97–102.
Richardson, M. and D. Warnock (2008). Other invasive yeast infections. Fungal Infect. 27: 346–353.
Romani, L. (2004). Immunity to fungal infections. Nat. Rev. Immunol. 4: 11–24.
Richardson, M. (2005). Changing patterns and trends in systemic fungal infections. J. Antimicrob. Chemother. 56: 5–11.
De Pauw, B., T. Walsh, J. Donnelly, D. Stevens, J. Edwards, and T. Calandra (2008). Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin. Infect. Dis. 46: 1813–1821.
Klaenhammer, T., M. Kleerebezem, M. Kopp, and M. Rescigno (2012). The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol. 12: 728–734.
CDC (2017). Types of Fungal Diseases Fungal Diseases. Cdc.gov. Retrieved 6 September 2017; https://www.cdc.gov/fungal/diseases/index.html#one.
Konkel, L. (2017). Fungal diseases are on the rise. Is environmental change to blame?. Ensia. Retrieved 6 September 2017, from https://ensia.com/features/19036/.
Dworecka-Kaszak, B. (2008). Animals as a potential source of human fungal infections. Wiad. Parazytol. 54: 101–108.
Warris, A. and P. Verweij (2005). Clinical implications of environmental sources for Aspergillus. Med. Mycol. 43: 59–65.
Burge, H. (2010). Sources and control of opportunistic fungi in the hospital environment. Environ. Rep. 8(1).
Bartley, J. (2007). Hospital construction: stirring up trouble. Eng. Sys. 24: e36.
Kanamori, H., W. Rutala, E. Sickbert-Bennett, and D. Weber (2015). Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin. Infect. Dis. 61: 433–444.
Fisher, M., D. Henk, C. Briggs, J. Brownstein, L. Madoff, S. McCraw, and S. Gurr (2012). Emerging fungal threats to animal, plant and ecosystem health. Nature 484: 186–194.
Olsen, L., E. Relman, and L. Pray, (2011). Fungal diseases: an emerging threat to human, animal and plant health. https://www.nap.edu/read/13147/chapter/1.
Rosenzweig, C., A. Iglesias, X. Yang, P. Epstein, and E. Chivian (2001). Climate change and extreme weather events; Implications for food production, plant diseases, and pests. Global Change Human Health 2: e1023.
Green, A., N. Victoria, and D. Fisman (2008). Climate change and infectious diseases in North America: the road ahead. Can. Med. Assoc. 178: e081325.
La Porta, N., P. Capretti, I. Thomsen, R. Kasanen, A. Hietala, and K. Von Weissenberg (2008). Forest pathogens with higher damage potential due to climate change in Europe. Can. J. Plant Pathol. 30: 177–195.
Garcia-Solache, M. and A. Casadevall (2010). Global warming will bring new fungal diseases for mammals. Mbio 1: e00061.
Baddley, J., T. Stroud, D. Salzman, and P. Pappas (2001). Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32: 1319–1324.
Singh, N. (2001). Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin. Infect. Dis. 33: 1692–1696.
Eggimann, P., J. Garbino, and D. Pittet (2003). Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect. Dis. 3: 685–702.
Garbino, J., L. Kolarvo, P. Rohner, D. Lew, P. Pichna, and D. Pittet (2002). Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 81: 425–433.
Clark, T. and R. Hajjeh (2002). Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 15: 569–574.
Hobson, R. P. (2003). The global epidemiology of invasive Candida infections–is the tide turning? J. Hosp. Infect. 55: 159–168.
Cornet, M., L. Fleury, C. Maslo, J. Bernard, and G. Brücker (2002). Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J. Hosp. Infect. 51: 288–296.
Armstrong-James, D., G. Meintjes, and G. Brown (2014). A neglected epidemic: fungal infections in HIV/AIDS. Trends Microbiol. 22: 120–127.
Trick, W., S. Fridkin, J. Edwards, R. Hajjeh, and R. Gaynes (2002). Secular trend of hospital?acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin. Infect. Dis. 35: 627–630.
Pfaller, M. and D. Diekema (2004). Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42: 4419–4431.
Redding, S., M. Dahiya, W. Kirkpatrick, B. Coco, T. Patterson, and A. Fothergill (2004). Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 97: 47–52.
Bennett, J., K. Izumikawa, and K. Marr (2004). Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48: 1773–1777.
Marr, K., R. Carter, F. Crippa, A. Wald, and L. Corey (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34: 909–917.
Nucci, M. (2003). Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis. 16: 607–612.
Kauffman, C. (2004). Zygomycosis: Reemergence of an old pathogen. Clin. Infect. Dis. 39: 588–590.
Husain, S., B. Alexander, P. Munoz, R. Avery, S. Houston, and T. Pruett (2003). Opportunistic mycelial fungal infections in organ transplant recipients: Emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. 37: 221–229.
Perea, S., T. Patterson, and G. Eliopoulos (2002). Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35: 1073–1080.
Nucci, M. and K. Marr (2005). Emerging fungal diseases. Clin. Infect. Dis. 41: 521–526.
Netea, M., L. Joosten, J. Van Der Meer, B. Kullberg, and F. Van De Veerdonk (2015). Immune defence against Candida fungal infections. Nat. Rev. Immunol. 15: 630–642.
Brown, G. D. (2011). Innate antifungal immunity: the key role of phagocytes. Annu. Rev. Immunol. 29: 1–21.
Conti, H. R., F. Shen, and N. Nayyar (2009). Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206: 299–311.
Brown, G., D. Denning, N. Gow, S. Levitz, M. Netea, and T. White (2012). Hidden killers: Human fungal infections. Sci. Trans. Med. 4: e3004404.
Jarvis, J., A. Percival, S. Bauman, J. Pelfrey, G. Meintjes, and G. Williams (2011). Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53: 1019–1023.
Cole, D., N. Govender, A. Chakrabarti, J. Sacarlal, and D. Denning (2017). Improvement of fungal disease identification and management: Combined health systems and public health approaches. Lancet Infect. Dis. 17: e30308.
Marr, K., S. Balajee, L. McLaughlin, M. Tabouret, C. Bentsen, and T. Walsh (2004). Detection of Galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J. Infect. Dis. 190: 641–649.
Clancy, C., R. Jaber, H. Leather, J. Wingard, B. Staley, and L. Wheat (2007). Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol. 45: 1759–1765.
Kosmidis, C. and D. Denning (2015). Republished: The clinical spectrum of pulmonary aspergillosis. Postgraduate Med. J. 91: 403–410.
Ostrosky-Zeichner, L., A. Casadevall, J. Galgiani, F. Odds, J. Rex (2010). An insight into the antifungal pipeline: Selected new molecules and beyond. Nat. Rev. Drug Dis. 9: 719–727.
Denning, D. and W. Hope (2010). Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 18:195–204.
Brown, G., D. Denning, S. Levitz (2012). Tackling human fungal infections. Science 336: 647–647.
Badiee, P. and Z. Hashemizadeh (2014). Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J. Med. Res. 139: 195–204.
Stevens, D., V. Kan, M. Judson, V. Morrison, S. Dummer, and D. Denning (2000). Practice guidelines for diseases caused by Aspergillus. Clin. Infect. Dis. 30: 696–709.
Allen, D., D. Wilson, R. Drew, and J. Perfect (2015). Azole antifungals: 35 years of invasive fungal infection management. Expert Rev. Anti-Infect. Ther. 13: 787–798.
Cassone, A. (2008). Fungal vaccines: real progress from real challenges. Lancet Infect. Dis. 8: 114–124.
Hong, G., M. White, N. Lechtzin, N. E. West, R. Averyd, H. Miller, R. Lee, R. J. Lovari, C. Massire, L. B. Blyn, X. Liang, D. A. Dutton, J. Fu, B. L. Wickes, N. P. Wiederhold, and S. X. Zhang (2017). Fatal disseminated Rasamsonia infection in cystic fibrosis post-lung transplantation. J. Cystic. Fibrosis. 17: 3–7.
Singh, K., M. R. Capoor, D. Nair, and K. T. Bhowmik (2017). Spectrum of fungal infection in head and neck cancer patients on chemoradiotherapy. J. Egypt Nat. Cancer Inst. 29: 33–37.
Byrnes, E. J., K. H. Bartlett, J. R. Perfect, and J. Heitman (2011). Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 13: 895–907.
Limper, H., A. Adenis, T. Le, and T. S. Harrison (2017). Fungal infections in HIV/AIDS. Lancet Infect. Dis. 17: 30303–30311.
Rossmann, S. N., P. L. Cernoch, J. R. Davis (1996). Dematiaceous fungi are an increasing cause of human disease. Clin. Infect. Dis. 22: 73–80.
Melnychuk, M., B. D. Emt, and D. P. Sole (2017). A rare central nervous system fungal infection resulting from brown heroin use Eric. J. Emerg. Med. 52: 314–317.
Bandh, S. A., A. N. Kamili, B. A. Ganai, and B. A. Lone (2016). Opportunistic fungi in lake water and fungal infections in associated human population in Dal Lake, Kashmir. Microbial Pathogen. 93: 105–110.
Azadeh, N., A. H. Limper, E. M. Carmona, J. H. Ryu (2017). The role of infection in interstitial lung diseases: A review. Chest 152: 842–852.
Pahlavan, S. and N. N. Bhatia (2016). Fungal spine. Sem. Spine Surg. 28: 163–172.
Gugnani, H. C. and D. W. Denning (2016). Burden of serious fungal infections in the Dominican Republic. J. Infect. Public Health 9: 7–12.
Acknowledgments
This work was supported by the 2016 Yeungnam University Research Grant. Also, we acknowledge financial support from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2014R1A5A1009799).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bajpai, V.K., Khan, I., Shukla, S. et al. Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Biotechnol Bioproc E 24, 436–444 (2019). https://doi.org/10.1007/s12257-018-0477-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12257-018-0477-0